A new analysis commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA) found the new Medicare Part D drug price negotiation program could raise out-of-pocket costs in 2026 for 3.5 million seniors because formulary placement will require they pay copays instead of coinsurance, meaning they won’t fully benefit from the new out-of-pocket limit in Part D. The report conducted by Milliman actuaries and released Tuesday (June 25) found setting maximum fair prices for selected drugs as a result of...